At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VYGR Voyager Therapeutics
Closed Mourning Day 01-08 16:00:00 EST
5.73
-0.19
-3.21%
盘后5.73
+0.000.00%
16:01 EST
High5.96
Low5.66
Vol354.21K
Open5.91
D1 Closing5.92
Amplitude4.98%
Mkt Cap313.00M
Tradable Cap247.58M
Total Shares54.63M
T/O2.03M
T/O Rate0.82%
Tradable Shares43.21M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Should Weakness in Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.